Carvedilol therapy in pediatric patients with congestive heart failure

A study investigating clinical and pharmacokinetic parameters

Stephanie Läer, Thomas S. Mir, Frederike Behn, Michele Eiselt, Hasso Scholz, Andrea Venzke, Bernd Meibohm, Jochen Weil

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Objective: Our purpose was to evaluate the clinical effect of carvedilol among pediatric patients with congestive heart failure (CHF) who did not respond to standard therapy and to assess the pharmacokinetics of carvedilol among these children. Methods: In this prospective, open intervention trial with blinded interpretation of selected end points, patients with CHF who did not improve on standard therapy, including digoxin, angiotensin-converting enzyme inhibitors, and diuretics, were treated with oral carvedilol in a ramped dosing scheme. Clinical parameters (ejection fraction, fractional shortening, and modified Ross score) were assessed before initiation of treatment and monthly for 6 months. Pharmacokinetic profiles of carvedilol were determined over the first 12-hour period after the initial dose in study patients, and for comparison, in 9 healthy adult volunteers. Results: Fifteen patients (aged 6 weeks to 19 years) were enrolled in the study, including 10 patients with dilated cardiomyopathy and 5 with CHF secondary to congenital heart disease. All 15 patients tolerated carvedilol for the duration of the trial, and all achieved maximum target dosing. After 6 months of carvedilol therapy, ejection fraction increased (36% vs 54%; P < .05) and modified Ross Score improved (5 ± 2 vs 3 ± 3; P < .05). Elimination half-life was about 50% shorter in pediatric CHF patients compared with healthy adult volunteers (2.9 vs 5.2 hours; P < .05). Conclusions: Pediatric patients with CHF not responding to standard therapy may benefit from oral carvedilol treatment. The observed increased elimination of carvedilol in children suggests that optimal dosing strategies need to be further defined among the pediatric population.

Original languageEnglish (US)
Pages (from-to)916-922
Number of pages7
JournalAmerican Heart Journal
Volume143
Issue number5
DOIs
StatePublished - Jan 1 2002

Fingerprint

Heart Failure
Pharmacokinetics
Pediatrics
Therapeutics
Healthy Volunteers
Clinical Studies
carvedilol
Digoxin
Dilated Cardiomyopathy
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Half-Life
Heart Diseases
Population

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Carvedilol therapy in pediatric patients with congestive heart failure : A study investigating clinical and pharmacokinetic parameters. / Läer, Stephanie; Mir, Thomas S.; Behn, Frederike; Eiselt, Michele; Scholz, Hasso; Venzke, Andrea; Meibohm, Bernd; Weil, Jochen.

In: American Heart Journal, Vol. 143, No. 5, 01.01.2002, p. 916-922.

Research output: Contribution to journalArticle

Läer, Stephanie ; Mir, Thomas S. ; Behn, Frederike ; Eiselt, Michele ; Scholz, Hasso ; Venzke, Andrea ; Meibohm, Bernd ; Weil, Jochen. / Carvedilol therapy in pediatric patients with congestive heart failure : A study investigating clinical and pharmacokinetic parameters. In: American Heart Journal. 2002 ; Vol. 143, No. 5. pp. 916-922.
@article{245cc890871c4ff5a238c8566b4f9cc6,
title = "Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters",
abstract = "Objective: Our purpose was to evaluate the clinical effect of carvedilol among pediatric patients with congestive heart failure (CHF) who did not respond to standard therapy and to assess the pharmacokinetics of carvedilol among these children. Methods: In this prospective, open intervention trial with blinded interpretation of selected end points, patients with CHF who did not improve on standard therapy, including digoxin, angiotensin-converting enzyme inhibitors, and diuretics, were treated with oral carvedilol in a ramped dosing scheme. Clinical parameters (ejection fraction, fractional shortening, and modified Ross score) were assessed before initiation of treatment and monthly for 6 months. Pharmacokinetic profiles of carvedilol were determined over the first 12-hour period after the initial dose in study patients, and for comparison, in 9 healthy adult volunteers. Results: Fifteen patients (aged 6 weeks to 19 years) were enrolled in the study, including 10 patients with dilated cardiomyopathy and 5 with CHF secondary to congenital heart disease. All 15 patients tolerated carvedilol for the duration of the trial, and all achieved maximum target dosing. After 6 months of carvedilol therapy, ejection fraction increased (36{\%} vs 54{\%}; P < .05) and modified Ross Score improved (5 ± 2 vs 3 ± 3; P < .05). Elimination half-life was about 50{\%} shorter in pediatric CHF patients compared with healthy adult volunteers (2.9 vs 5.2 hours; P < .05). Conclusions: Pediatric patients with CHF not responding to standard therapy may benefit from oral carvedilol treatment. The observed increased elimination of carvedilol in children suggests that optimal dosing strategies need to be further defined among the pediatric population.",
author = "Stephanie L{\"a}er and Mir, {Thomas S.} and Frederike Behn and Michele Eiselt and Hasso Scholz and Andrea Venzke and Bernd Meibohm and Jochen Weil",
year = "2002",
month = "1",
day = "1",
doi = "10.1067/mhj.2002.121265",
language = "English (US)",
volume = "143",
pages = "916--922",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Carvedilol therapy in pediatric patients with congestive heart failure

T2 - A study investigating clinical and pharmacokinetic parameters

AU - Läer, Stephanie

AU - Mir, Thomas S.

AU - Behn, Frederike

AU - Eiselt, Michele

AU - Scholz, Hasso

AU - Venzke, Andrea

AU - Meibohm, Bernd

AU - Weil, Jochen

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objective: Our purpose was to evaluate the clinical effect of carvedilol among pediatric patients with congestive heart failure (CHF) who did not respond to standard therapy and to assess the pharmacokinetics of carvedilol among these children. Methods: In this prospective, open intervention trial with blinded interpretation of selected end points, patients with CHF who did not improve on standard therapy, including digoxin, angiotensin-converting enzyme inhibitors, and diuretics, were treated with oral carvedilol in a ramped dosing scheme. Clinical parameters (ejection fraction, fractional shortening, and modified Ross score) were assessed before initiation of treatment and monthly for 6 months. Pharmacokinetic profiles of carvedilol were determined over the first 12-hour period after the initial dose in study patients, and for comparison, in 9 healthy adult volunteers. Results: Fifteen patients (aged 6 weeks to 19 years) were enrolled in the study, including 10 patients with dilated cardiomyopathy and 5 with CHF secondary to congenital heart disease. All 15 patients tolerated carvedilol for the duration of the trial, and all achieved maximum target dosing. After 6 months of carvedilol therapy, ejection fraction increased (36% vs 54%; P < .05) and modified Ross Score improved (5 ± 2 vs 3 ± 3; P < .05). Elimination half-life was about 50% shorter in pediatric CHF patients compared with healthy adult volunteers (2.9 vs 5.2 hours; P < .05). Conclusions: Pediatric patients with CHF not responding to standard therapy may benefit from oral carvedilol treatment. The observed increased elimination of carvedilol in children suggests that optimal dosing strategies need to be further defined among the pediatric population.

AB - Objective: Our purpose was to evaluate the clinical effect of carvedilol among pediatric patients with congestive heart failure (CHF) who did not respond to standard therapy and to assess the pharmacokinetics of carvedilol among these children. Methods: In this prospective, open intervention trial with blinded interpretation of selected end points, patients with CHF who did not improve on standard therapy, including digoxin, angiotensin-converting enzyme inhibitors, and diuretics, were treated with oral carvedilol in a ramped dosing scheme. Clinical parameters (ejection fraction, fractional shortening, and modified Ross score) were assessed before initiation of treatment and monthly for 6 months. Pharmacokinetic profiles of carvedilol were determined over the first 12-hour period after the initial dose in study patients, and for comparison, in 9 healthy adult volunteers. Results: Fifteen patients (aged 6 weeks to 19 years) were enrolled in the study, including 10 patients with dilated cardiomyopathy and 5 with CHF secondary to congenital heart disease. All 15 patients tolerated carvedilol for the duration of the trial, and all achieved maximum target dosing. After 6 months of carvedilol therapy, ejection fraction increased (36% vs 54%; P < .05) and modified Ross Score improved (5 ± 2 vs 3 ± 3; P < .05). Elimination half-life was about 50% shorter in pediatric CHF patients compared with healthy adult volunteers (2.9 vs 5.2 hours; P < .05). Conclusions: Pediatric patients with CHF not responding to standard therapy may benefit from oral carvedilol treatment. The observed increased elimination of carvedilol in children suggests that optimal dosing strategies need to be further defined among the pediatric population.

UR - http://www.scopus.com/inward/record.url?scp=0036271469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036271469&partnerID=8YFLogxK

U2 - 10.1067/mhj.2002.121265

DO - 10.1067/mhj.2002.121265

M3 - Article

VL - 143

SP - 916

EP - 922

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -